Overview

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Status:
Unknown status

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Fukushima Medical University

Collaborator:

Human Genome Center, Institute of Medical Science, University of Tokyo

Treatments:

Gemcitabine
Vaccines